Advanced Holdings Ltd. approved the appointment of Mr. Danny Lien Chong Tuan as non-executive Independent Director, Chairman of the Remuneration Committee, and Member of the Audit Committee and Nominating Committee, effective from April 29, 2024. Working Experience: 2021-Present: Chief Executive Officer, Genesis Solutions Pte Ltd. 2018-2019 Chief Commercial Officer, Amos Group Ltd. 2004-2019 Founder & Managing Director, Amos International (S) Pte Ltd. Other DirectorShips Past: Amos Group Ltd. Amos International (S) Pte Ltd. Amos International Holdings Pte Ltd. Amos Asia Pte Ltd. Institute of Human Resource Professional Ltd. Other DirectorShips Present: Genesis Solutions Pte Ltd. Mirai Marine Valves Pte Ltd. Cold Chain Company Pte Ltd. Imafit Pte Ltd. Bemo MMP Rail Systems Pte Ltd. Alpha & Omega Media Production Pte Ltd. Director Experience Details: Amos Group Limited. Appointment of Danny Lien Chong Tuan ("Mr Lien") as Independent Director of the Company.

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. Professional Qualifications: Advanced Certificate in Learning & Performance from Institute of Adult Learning Owner President Management (OPM) Program from Harvard Business School Masters of Business Administration (MBA) from University of Chicago Booth School of Business Bachelor of Business Administration (BBA) from University of Miami, Florida.

Reason for director to not undergo training: Mr. Lien served as Non-Executive Director of Amos Group Limited listed on the Singapore Exchange Securities Trading Limited, from 13 February 2019 to 1 September 2020. The Company will make arrangements for Mr. Lien to complete Sustainability Training course as prescribed by the Exchange within one year from the date of appointment to the Board.